Pular para o conteúdo
Linfoma cutâneo de células T
ORPHA:171901CID-10 · C84.0DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Dermatológico
Também conhecida comoLinfoma T cutâneo

Linfoma cutâneo de células T é um grupo de linfomas não-Hodgkin que se manifestam primariamente na pele, apresentando-se como pápulas ou placas eritematosas. Pode estar associado a sintomas sistêmicos como calafrios, hepatoesplenomegalia e hipercalcemia.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEsboçohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

Mantido pelo Disease Twin100% com fonte · atualizado 25/09/2026Revisão médica pendente
Informacoes curadas por IA — podem conter imprecisoes

Visão geral

O Linfoma cutâneo de células T (em inglês, Primary cutaneous T-cell lymphoma) é uma condição rara identificada pelos códigos MONDO:0015758 e CID-10 C84.0, com uma prevalência estimada entre 1 e 5 casos para cada 10.000 indivíduos.[1][2]

Sinais e sintomas

As manifestações clínicas relatadas incluem diversas alterações dermatológicas como pápula eritematosa, placa eritematosa, placa cutânea, eritema, dermatite psoriasiforme, dermatite eczematoide, prurido, neoplasia da pele, pele rígida, pele redundante e cutis laxa.[1][2]

Também são descritos sinais e sintomas sistêmicos, linfonodais e laboratoriais, incluindo linfoma, linfoma de Hodgkin, linfadenopatia, anormalidade dos linfonodos, hepatoesplenomegalia, calafrios, edema facial, autoimunidade, anemia, pancitopenia e hemofagocitose, além de hipercalcemia, nefrocalcinose e lesão renal aguda.[1][2]

Causas genéticas

Estudos e bases genéticas associam a condição aos genes HAVCR2 (Hepatitis A virus cellular receptor 2), TNFRSF1B (Tumor necrosis factor receptor superfamily member 1B), CD28 (T-cell-specific surface glycoprotein CD28), CTLA4 (Cytotoxic T-lymphocyte protein 4), NPM1 (Nucleophosmin) e TYK2 (Non-receptor tyrosine-protein kinase TYK2).[1][3]

Diagnóstico

Na investigação diagnóstica e genética, constam catalogados 336 testes genéticos e 88 variantes registradas na base ClinVar relacionadas a esta condição.[1][3][4]

Tratamento e manejo

No âmbito do Sistema Único de Saúde (SUS), o nível de cobertura registrado para a doença é classificado como 'Sem cobertura SUS', não havendo medicamentos dispensados nem procedimentos específicos listados em nossos registros.[1][4]

Atualmente, encontram-se registrados 70 ensaios clínicos ativos avaliando abordagens para a condição.[1][4]

Tratamentos citados na literatura

A literatura científica biomédica cita menções a fármacos em estudos relacionados ao Linfoma cutâneo de células T. Estas informações representam associações mineradas na literatura científica e NÃO constituem recomendação clínica ou prescrição de tratamento: Brentuximab Vedotin (26 publicações), Methotrexate (18 publicações), Cyclophosphamide (7 publicações), Fluorodeoxyglucose F18 (5 publicações), Doxorubicin (4 publicações), Etoposide (4 publicações), Prednisone (4 publicações), Bexarotene (3 publicações), 10 propargyl 10 deazaaminopterin (2 publicações) e Anthracyclines (2 publicações).[4]

Fontes numeradas em Referências.

Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.

💬
EM LINGUAGEM SIMPLES

O **linfoma cutâneo de células T** é uma neoplasia rara originada nos glóbulos brancos da defesa que afeta prioritariamente a pele. Ele costuma provocar coceira intensa, vermelhidão, descamação e a formação de manchas ou pequenas placas avermelhadas na pele. Também podem ocorrer ínguas pelo corpo, alterações no fígado e no baço, além de alterações nos exames de sangue. No Brasil, a patologia não consta na lista oficial de PCDTs de doenças raras do Ministério da Saúde, sendo acompanhada diretamente pela rede de atenção especializada do SUS.

📋
Informacoes curadas por IA — podem conter imprecisoes

Linfoma cutâneo de células T é um grupo de linfomas não-Hodgkin que se manifestam primariamente na pele, apresentando-se como pápulas ou placas eritematosas. Pode estar associado a sintomas sistêmicos como calafrios, hepatoesplenomegalia e hipercalcemia.

Pesquisas ativas
70 ensaios
474 total registrados no ClinicalTrials.gov
Publicações científicas
329 artigos
Último publicado: 2026 Mar
Em pesquisa
10 moléculas
DEXAMETHASONE SODIUM PHOSPHATE, PREDNISOLONE, MOGAMULIZUMAB

O que está sendo pesquisado

10 moléculas em estudo — nenhuma com registro para esta doença
Ver detalhes e fases →
DEXAMETHASONE SODIUM PHOSPHATEPREDNISOLONEMOGAMULIZUMABMETHOTREXATEDEXAMETHASONEPREDNISONEBEXAROTENEBRENTUXIMAB VEDOTIN
Aparecer aqui significa que a molécula foi estudada nesta doença, não que trate. Converse com seu médico.

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
24.0
Europe
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C84.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧬
Pele e cabelo
17 sintomas
🩸
Sangue
8 sintomas
🫃
Digestivo
3 sintomas
🫘
Rins
2 sintomas
🛡️
Imunológico
1 sintomas
😀
Face
1 sintomas

+ 19 sintomas em outras categorias

Características mais comuns

—
Pápula eritematosa
—
Placa eritematosa
—
Calafrios
—
Hepatoesplenomegalia
—
Linfoma
—
Linfoma de Hodgkin
54sintomas
Sem dados (54)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 54 características clínicas mais associadas, ordenadas por frequência.

Pápula eritematosaErythematous papule
Placa eritematosaErythematous plaque
CalafriosChills
HepatoesplenomegaliaHepatosplenomegaly
LinfomaLymphoma

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico329PubMed
Últimos 10 anos184publicações
Pico202424 papers
Linha do tempo
2026Hoje · 2026🧪 1989Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição.

HAVCR2Hepatitis A virus cellular receptor 2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Interleukin-2 family signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
25.9 TPM
Baço
24.8 TPM
Sangue
18.0 TPM
Brain Spinal cord cervical c-1
14.4 TPM
Rim - Córtex
11.5 TPM
OUTRAS DOENÇAS (1)
subcutaneous panniculitis-like T-cell lymphoma
HGNC:18437UniProt:Q8TDQ0
TNFRSF1BTumor necrosis factor receptor superfamily member 1BCandidate gene tested inModerado
VIAS BIOLÓGICAS (4)
Neutrophil degranulationTNFR2 non-canonical NF-kB pathwayTNFs bind their physiological receptorsInterleukin-4 and Interleukin-13 signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
474.3 TPM
Baço
180.8 TPM
Tecido adiposo
110.3 TPM
Linfócitos
105.9 TPM
Pulmão
100.4 TPM
OUTRAS DOENÇAS (2)
mycosis fungoidesSezary syndrome
HGNC:11917UniProt:P20333
CD28T-cell-specific surface glycoprotein CD28Candidate gene tested inRestrito
VIAS BIOLÓGICAS (2)
Co-stimulation by CD28Nef mediated downregulation of CD28 cell surface expression
MECANISMO DE DOENÇA

Immunodeficiency 123 with HPV-related verrucosis

An autosomal recessive immunologic disorder characterized by susceptibility to human papilloma virus (HPV) infections and the development of HPV-related common verrucosis in the first decade of life. In some patients with HPV2 infection, warts may progress to severe generalized hyperkeratotic cutaneous papillomatosis with cutaneous horns ('tree-man' phenotype). In patients with HPV4 infection, warts remains stable and may even regress with age.

OUTRAS DOENÇAS (3)
immunodeficiency 123 with HPV-related verrucosismycosis fungoidesSezary syndrome
HGNC:1653UniProt:P10747
CTLA4Cytotoxic T-lymphocyte protein 4Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (3)
Co-stimulation by CD28Co-inhibition by CTLA4RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
5.8 TPM
Intestino delgado
4.9 TPM
Pulmão
4.3 TPM
Testículo
2.5 TPM
Sangue
1.8 TPM
OUTRAS DOENÇAS (6)
autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiencysystemic lupus erythematosusgranulomatosis with polyangiitismycosis fungoides
HGNC:2505UniProt:P16410
NPM1NucleophosminCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (4)
PKR-mediated signalingTP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertainNuclear import of Rev proteinNuclear events stimulated by ALK signaling in cancer
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1517.5 TPM
Fibroblastos
1222.0 TPM
Ovário
1031.3 TPM
Cervix Endocervix
640.5 TPM
Útero
622.0 TPM
OUTRAS DOENÇAS (8)
acute myeloid leukemiaacute promyelocytic leukemiaacute myeloid leukemia with NPM1 somatic mutationsdyskeratosis congenita
HGNC:7910UniProt:P06748
TYK2Non-receptor tyrosine-protein kinase TYK2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (10)
Interferon alpha/beta signalingRegulation of IFNA/IFNB signalingPotential therapeutics for SARSInterleukin-20 family signalingOther interleukin signaling
MECANISMO DE DOENÇA

Immunodeficiency 35

A primary immunodeficiency characterized by recurrent skin abscesses, pneumonia, and highly elevated serum IgE.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
100.5 TPM
Baço
95.0 TPM
Sangue
78.6 TPM
Pulmão
65.9 TPM
Nervo tibial
65.4 TPM
OUTRAS DOENÇAS (3)
immunodeficiency 35primary cutaneous anaplastic large cell lymphomalymphomatoid papulosis
HGNC:12440UniProt:P29597

Medicamentos e terapias

DEXAMETHASONE SODIUM PHOSPHATEPhase 4

Mecanismo: Glucocorticoid receptor agonist

PREDNISOLONEPhase 4

Mecanismo: Glucocorticoid receptor agonist

MOGAMULIZUMABPhase 4

Mecanismo: C-C chemokine receptor type 4 cross-linking agent

METHOTREXATEPhase 4

Mecanismo: Dihydrofolate reductase inhibitor

DEXAMETHASONEPhase 4

Mecanismo: Glucocorticoid receptor agonist

PREDNISONEPhase 4

Mecanismo: Glucocorticoid receptor agonist

BEXAROTENEPhase 3

Mecanismo: Retinoid X receptor agonist

BRENTUXIMAB VEDOTINPhase 3

Mecanismo: Tubulin inhibitor

NALOXONEPhase 3

Mecanismo: Opioid receptors; mu/kappa/delta antagonist

ZANOLIMUMABPhase 3

Mecanismo: T-cell surface antigen CD4 other

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

88 variantes patogênicas registradas no ClinVar.

🧬 HAVCR2: GRCh37/hg19 5q33.2-34(chr5:154849998-164037131)x1 ()
🧬 HAVCR2: NM_032782.5(HAVCR2):c.833A>G (p.Asn278Ser) ()
🧬 HAVCR2: NM_032782.5(HAVCR2):c.319A>T (p.Ile107Phe) ()
🧬 HAVCR2: NC_000005.9:g.(?_155338082)_(156899968_?)del ()
🧬 HAVCR2: GRCh37/hg19 5q33.1-35.2(chr5:150535183-172906793)x3 ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado7
3Fase 37
2Fase 237
1Fase 129
·Pré-clínico30
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 100 ensaios
✓ Aprovados — podem ser usados hoje
DEXAMETHASONE SODIUM PHOSPHATEPREDNISOLONEMOGAMULIZUMABMETHOTREXATEDEXAMETHASONEPREDNISONE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Linfoma cutâneo de células T

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 16 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

40 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07192471 · A First-in-Human Study of KK2223 in Participants With Relaps…Recrutando
PHASE1🇮🇹 Itália · 🇪🇸 Espanha · 🇺🇸 Estados Unidos
NCT07356245 · Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transpl…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07195916 · A Study to Evaluate INCA036873 in Participants With Advanced…Recrutando
PHASE1🇦🇺 Austrália · 🇧🇪 Bélgica · 🇩🇰 Dinamarca +2
NCT07283822 · Amping up With PemJAKRecrutando
PHASE2🇺🇸 Estados Unidos
NCT07047885 · Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTC…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07754890 · Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecrutando
PHASE1, PHASE2🇨🇳 China
NCT06860880 · Combating Cancer-Related Fatigue: A Personalized Supportive …Recrutando
NA🇺🇸 Estados Unidos
NCT07022964 · CD5 CAR T-Cell Therapy for r/r T-cell LymphomasRecrutando
PHASE1, PHASE2🇨🇳 China
NCT06925464 · CD7 CAR T-Cell Therapy for r/r T-cell LymphomasRecrutando
PHASE1, PHASE2🇨🇳 China
NCT06914037 · A Clinical Study of CHT101 in CD70-Positive Relapsed or Refr…Recrutando
PHASE1🇨🇳 China
NCT06854653 · A Phase 2 Study of PTX 100 in Patients With Relapsed/Refract…Recrutando
PHASE2🇦🇺 Austrália · 🇫🇷 França · 🇮🇹 Itália +1
NCT06698822 · A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06588868 · Systemic Therapies in the Treatment of Cutaneous T-cell Lymp…Recrutando
🇮🇹 Itália
NCT06716658 · JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Re…Recrutando
PHASE2🇨🇳 China
NCT05996185 · Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients Wi…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06436677 · A Study of Molecular Subtyping-based Therapeutic Strategies …Recrutando
🇨🇳 China
NCT06382844 · Novel Flow-cytometry Approaches to Improve the Detection of …Recrutando
🇪🇸 Espanha
NCT04234048 · Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refracto…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT05956041 · Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04670874 · Quality of Life in Cutaneous Lymphoma Patients Using the Ski…Recrutando
🇺🇸 Estados Unidos
NCT05313243 · Pembrolizumab and Brentuximab Vedotin in Subjects With Relap…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04128072 · Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin…Recrutando
PHASE2🇩🇰 Dinamarca · 🇫🇷 França · 🇩🇪 Alemanha +4
NCT04930653 · Extracorporeal Photopheresis and Mogamulizumab for the Treat…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT05518851 · TreAtments and outComes in paTients With prImary CutAneous L…Recrutando
🇨🇳 China
NCT04848064 · Third-Party Natural Killer Cells and Mogamulizumab for the T…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT05333367 · MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal…Recrutando
NA🇫🇷 França
NCT05296304 · A Study of Bexarotene Combined With Radiotherapy in People W…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT05680558 · Photopheresis in Early-stage Mycosis FungoidesRecrutando
PHASE2🇺🇸 Estados Unidos
NCT04904146 · Predictive and Prognostic Biomarkers in Patients With Mycosi…Recrutando
🇸🇪 Suécia
NCT04045470 · A Pilot of a Microdevice For In Situ Candidate Drug Screenin…Recrutando
NA🇺🇸 Estados Unidos
NCT04014374 · Post-authorization Safety Study of Allogeneic Hematopoietic …Recrutando
🇺🇸 Estados Unidos
NCT03932279 · Characterization of the Microbiome in Cutaneous T Cell Lymph…Recrutando
🇺🇸 Estados Unidos
NCT03017820 · A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide a…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT03011814 · Durvalumab With or Without Lenalidomide in Treating Patients…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT02840747 · Tissue Repository: CTCL Collection ProtocolRecrutando
🇺🇸 Estados Unidos
NCT01087333 · Collection of Human Samples to Study Hairy Cell and Other Le…Recrutando
🇺🇸 Estados Unidos
NCT01137825 · Registry of Older Patients With CancerRecrutando
🇺🇸 Estados Unidos
NCT01137643 · Tissue, Blood, and Body Fluid Sample Collection From Patient…Recrutando
🇺🇸 Estados Unidos
NCT00177268 · Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, …Recrutando
🇺🇸 Estados Unidos
NCT06665490 · Pilot Study to Characterize the Microbiome in Cutaneous T Ce…Por convite
🇺🇸 Estados Unidos

Outros ensaios clínicos

474 ensaios clínicos encontrados, 70 ativos.

Distribuição por fase
NCT07608549 · FLASH Pilot Phase 1 Safety StudyEm breve
NA
NCT07714187 · A Study of Topical Duvelisib in Participants With Early-stag…Em breve
PHASE1🇺🇸 Estados Unidos
NCT05728879 · Characterization of the Microbiome in Cutaneous T Cell Lymph…Em breve
EARLY_PHASE1🇺🇸 Estados Unidos
NCT07710781 · Study to Characterize Mismatched to Fully HLA-Matched Ossium…Em breve
NA
NCT07854639 · A Prospective Clinical Study of Zeprumetosta in Patients Wit…Em breve
PHASE2🇨🇳 China
NCT07682792 · Golidocitinib in Patients With Mycosis Fungoides/Sézary Synd…Em breve
PHASE2🇺🇸 Estados Unidos
NCT07781449 · Topical JAK-Inhibition of Early-Stage CTCLEm breve
PHASE2
NCT07658924 · Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell …Em breve
PHASE2
NCT07538960 · Epidemiology and Management of Cutaneous T-Cell Lymphoma at …Em breve
Costa Rica
NCT07535710 · Aclarubicin Plus Cyclophosphamide, Vincristine, and Predniso…Em breve
PHASE1, PHASE2🇨🇳 China
NCT07213882 · A Phase 1, Multicenter, Open-label, Prospective, First-in-hu…Em breve
EARLY_PHASE1
NCT07178457 · Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Po…Em breve
PHASE3
NCT07046663 · Long-term Assessment of Chlormethine Gel in Mycosis Fungoide…Em breve
🇮🇹 Itália
NCT06385522 · A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), …Em breve
PHASE1
NCT06651203 · Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézar…Em breve
NCT05205902 · TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone …Em breve
PHASE3
NCT04520529 · Identification of Prognostic Factors and New Therapeutic Tar…Em breve
NA
NCT06733441 · A Study of TLN-254 in Participants With Relapsed or Refracto…Ativo
PHASE1🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT05589896 · A First-in-Human Study of HLA-Partially to Fully Matched All…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06485219 · A Phase IIa Clinical Study of Purinostat Mesylate for Inject…Ativo
PHASE2🇨🇳 China
NCT05627245 · Testing the Safety of the Anti-cancer Drugs Tazemetostat and…Ativo
PHASE1🇺🇸 Estados Unidos
NCT04072458 · A Clinical Trial of BP1002 in Patients With Advanced Lymphoi…Ativo
PHASE1🇺🇸 Estados Unidos
NCT03385226 · A Trial Assessing the Effect of Pembrolizumab Combined with …Ativo
PHASE2🇬🇧 Reino Unido
NCT03602157 · Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ …Ativo
PHASE1🇺🇸 Estados Unidos
NCT03278782 · Study of Pembrolizumab (MK-3475) in Combination With Romidep…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT02520791 · Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients …Ativo
PHASE1🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02732275 · DS-3201b in Participants With LymphomasAtivo
PHASE1🇯🇵 Japão · 🇺🇸 Estados Unidos
NCT01352520 · SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL)…Ativo
PHASE2🇺🇸 Estados Unidos
NCT00935090 · 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients Wi…Ativo
🇺🇸 Estados Unidos
NCT00544115 · Donor Peripheral Stem Cell Transplant in Treating Patients W…Ativo
PHASE2
NCT01578499 · A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physic…Concluído
PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇦🇹 Áustria +9
NCT06113081 · Real World Experience With Mogamulizumab in the Treatment of…Concluído
🇮🇹 Itália
NCT05872854 · Treatment of Mycosis Fungoides With Hypericin Ointment and V…Concluído
PHASE2🇺🇸 Estados Unidos
NCT06285370 · A Study to Evaluate the Efficacy and Safety of KW-0761 in Ch…Concluído
PHASE4🇨🇳 China
NCT05827107 · Skin Barrier and Microbiome of CTCL PatientsConcluído
🇳🇱 Países Baixos
NCT05225584 · Safety, PK, PD, Clinical Activity of KT-333 in Adult Patient…Concluído
PHASE1🇺🇸 Estados Unidos
NCT05303480 · Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis …Concluído
NA🇳🇱 Países Baixos
NCT04998331 · A Spanish Medical Record Review of Adults With Relapsed or R…Concluído
🇪🇸 Espanha
NCT04955340 · A Phase 1, Open-label Study of the Absorption, Metabolism, E…Concluído
PHASE1🇬🇧 Reino Unido
NCT04774068 · Romidepsin and Parsaclisib for the Treatment of Relapsed or …Concluído
PHASE1🇺🇸 Estados Unidos
NCT05137847 · A Study of Remitoro in Participants With Recurrent or Refrac…Concluído
🇯🇵 Japão
NCT04447027 · Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenal…Concluído
PHASE1🇺🇸 Estados Unidos
NCT04312841 · Letermovir for the Prevention of Cytomegalovirus Reactivatio…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02342782 · Yttrium Y 90 Basiliximab and Combination Chemotherapy Before…Concluído
PHASE1🇺🇸 Estados Unidos
NCT03905135 · Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio…Concluído
PHASE1🇺🇸 Estados Unidos
NCT03902184 · IPH4102/Lacutamab Alone or in Combination With Chemotherapy …Concluído
PHASE2🇦🇹 Áustria · 🇧🇪 Bélgica · 🇫🇷 França +5
NCT03302728 · Brentuximab Vedotin and Lenalidomide in Patients With Relaps…Concluído
PHASE1🇦🇺 Austrália
NCT03458117 · T-VEC in Non-melanoma Skin CancerConcluído
PHASE1🇨🇭 Suíça
NCT03493451 · Study of BGB-A317 in Participants With Relapsed or Refractor…Concluído
PHASE2🇨🇦 Canadá · 🇨🇳 China · 🇫🇷 França +2
NCT03409432 · Brentuximab Vedotin and Lenalidomide in Treating Patients Wi…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03292406 · A Safety, Efficacy and Pharmacokinetics Study of CD11301 for…Concluído
PHASE2🇫🇷 França · 🇩🇪 Alemanha · 🇺🇸 Estados Unidos
NCT03380026 · Mechlorethamine Induced Contact Dermatitis Avoidance StudyConcluído
PHASE2🇺🇸 Estados Unidos
NCT02512497 · Romidepsin Maintenance After Allogeneic Stem Cell Transplant…Concluído
PHASE1🇺🇸 Estados Unidos
NCT03109353 · Modification of Extracorporeal Photopheresis in Cutaneous T-…Concluído
PHASE1, PHASE2🇳🇴 Noruega
NCT03192202 · AFM13 in Relapsed/Refractory Cutaneous LymphomasConcluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT02616965 · A Study to Assess the Feasibility of Romidepsin Combined Wit…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02689453 · Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alem…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02643303 · A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in …Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT02953301 · Resminostat for Maintenance Treatment of Patients With Advan…Concluído
PHASE2🇦🇹 Áustria · 🇧🇪 Bélgica · 🇫🇷 França +9
NCT02836886 · VircapSeq Virus Detection in Sézary SyndromeConcluído
🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
188 papers (10 anos)
#1

T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma.

Blood neoplasia2026 May
#2

Localized palmar mycosis fungoides: A case report.

Medicine2026 Jan 16

Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma, yet palmar MF is extremely rare and easily mistaken for chronic dermatoses such as psoriasis. Delayed recognition can lead to inappropriate treatment and worse outcomes. This case demonstrates how careful histopathology and immunohistochemistry can provide critical diagnostic clarity in atypical presentations. A 63-year-old woman presented with an 8-year history of erythema, dryness, scaling, and fissuring on both palms. The lesions had been misdiagnosed as psoriasis and showed no response to long-term topical calcipotriol. Histopathology of a palm biopsy revealed epidermotropism of atypical lymphocytes with cerebriform nuclei and Pautrier microabscesses. Immunohistochemistry demonstrated positivity for CD2, CD3, CD4, and CD45RO with immunophenotypic variation, confirming palmar MF. The patient was staged as early MF (IA-IB). Systemic therapy with intramuscular interferon α-2b, oral methylprednisolone, and acitretin was initiated due to chronicity, bilateral palm involvement, and resistance to topical therapy. Significant improvement was noted after 2 months. At the 1-year follow-up, her palms showed complete clearance of lesions with sustained remission. This case highlights the diagnostic pitfalls of palmar MF and underscores the necessity of early biopsy in patients with persistent, treatment-resistant palm dermatoses. Raising clinical awareness of this rare entity may prevent misdiagnosis, facilitate timely therapy, and ultimately improve patient prognosis.

#3

Radiotherapy dose-response of mycosis fungoides with large cell transformation.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026 Feb

Mycosis fungoides (MF) is the most prevalent subtype of primary cutaneous T-cell lymphoma. Large cell transformation of MF (LCTMF) is rare and confers a poor prognosis. Radiotherapy (RT) is an effective local treatment for LCTMF; however, dose-response data are limited. Eligibility for this retrospective study required biopsy-proven LCTMF with clinico-pathological correlation, diagnosed 1/1/1990-1/10/2021, and managed at Peter MacCallum Cancer Centre. 83 patients were eligible. Median age was 68 years, 63 (76 %) patients had cutaneous-only LCTMF at time of diagnosis. Median follow-up was 8.0 (95 % CI: 6-11) years. Details of 155 irradiated LCTMF lesions (from 49 patients) were available: 150 cutaneous, 5 extra-cutaneous. For cutaneous LCTMF, median equivalent dose in 2.0 Gy per fraction (EQD2, α/β of 10) was 30.6 (range, 4.7-46.3) Gy. Dose-response data were available for 141 cutaneous LCTMF lesions. Overall response rate (ORR) was 94 % (60 % complete response (CR), 35 % partial response). For cutaneous lesions treated with >12.0 Gy, ORR was 100 %. Increasing doses of RT were associated with greater CR rates: doses >36.0 Gy achieved 100 % CR rate. 22 (27 %) patients had unifocal cutaneous-only LCTMF and were treated with local RT-alone, median EQD2 36.0 Gy (range, 17.3-46.3 Gy). CR rate was 100 %. 9 (41 %) patients remained relapse-free (median follow-up, 3.2 years). Only 1 patient experienced infield-only recurrence at first relapse. LCTMF is radio-responsive, with EQD2 >12.0 Gy associated with 100 % ORR. Dose-response was observed, with EQD2 >36.0 Gy achieving 100 % CR rate. For unifocal cutaneous LCTMF, RT-alone achieved excellent infield control with possible curative potential in a proportion of patients.

#4

Histopathologic Spectrum of Primary Cutaneous T-Cell Lymphomas: Insights From a Vietnamese Case Series.

The American Journal of dermatopathology2026 Jan 01

Primary cutaneous T-cell lymphomas (PCTCLs) are a rare and heterogeneous group of extranodal non-Hodgkin lymphomas originating from skin-homing T cells. Most current knowledge about PCTCLs is derived from Western populations, with limited data available from Southeast Asia, including Vietnam. To characterize the clinical, histopathologic, and immunohistochemical features of PCTCLs in a cohort of Vietnamese patients. A retrospective case series was conducted involving 39 PCTCL cases. Demographic and clinical data were collected from medical records and archived clinical images. Histopathologic and immunohistochemical evaluations were independently performed by 3 pathologists, following the fifth edition of the WHO Classification of Haematolymphoid Tumours. Subcutaneous panniculitis-like T-cell lymphoma was most frequent (36%), followed by mycosis fungoides (MF, 28%) and primary cutaneous anaplastic large cell lymphoma (pcALCL, 15%). Subcutaneous panniculitis-like T-cell lymphoma predominantly affected young women, whereas MF and pcALCL occurred in older adults (median age, 64 years). Beyond canonical clinicopathologic features, notable findings included high rates of Pautrier microabscesses and eosinophilic infiltration in MF (each 73%), 1 ulcerated MF case, and 1 pcALCL with a CD4-/CD8- phenotype. Although clinicopathologic features largely aligned with established diagnostic criteria, several differences from international series were observed. These disparities likely reflect delayed diagnosis, referral bias toward more severe disease, and broader systemic and cultural factors in Vietnam, and constrained availability of advanced diagnostic assays, underscoring the need to strengthen clinicopathologic integration and expand access to specialized care.

#5

Bacterial skin colonization and systemic antibiotic treatment in patients with cutaneous T-cell lymphoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026 Jan

Bacterial colonization, particularly by Staphylococcus aureus (SA), is prevalent on the skin of patients with primary cutaneous T-cell lymphoma (CTCL). This study aimed to investigate risk factors for cutaneous bacterial and Staphylococcus aureus colonization and to evaluate their impact, together with systemic antibiotic use, on the prognosis of patients with CTCL. This retrospective study included 113 CTCL patients who underwent skin swab testing at Peking University First Hospital from 2010 to 2024. Eighty-five patients (75.2%) tested positive for bacterial skin colonization (SA, 60.2%). Ulcerated lesions significantly increased the likelihood of a positive result in bacterial/SA skin cultures (multivariate analysis). Additionally, advanced stages, the presence of tumors, erythroderma, lymphopenia, and eosinophilia were associated with an increased risk of positive skin cultures (Univariate analysis). Cox regression analysis indicated that skin bacterial/SA colonization and antibiotic intervention, were not correlated with overall survival (p > 0.05). This retrospective study presents data on the prevalence of bacterial skin colonization in Asian CTCL patients. Ulcerated lesions emerged as the most significant risk factor associated with cutaneous bacterial/SA colonization. In Asian patients with CTCL, neither bacterial or Staphylococcus aureus skin colonization was associated with a poorer prognosis, nor did short-term systemic antibiotic therapy improve outcomes.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC96 artigos no totalmostrando 182

2026

T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma.

Blood neoplasia
2025

Efficacy and tolerability of mogamulizumab in mycosis fungoides and Sézary Syndrome: a monocentric retrospective study.

Frontiers in oncology
2025

Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.

Cureus
2026

Localized palmar mycosis fungoides: A case report.

Medicine
2025

Unusual Presentation of Subcutaneous Panniculitis-Like T-Cell Lymphoma.

Clinical case reports
2026

Radiotherapy dose-response of mycosis fungoides with large cell transformation.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
2026

Clinical presentation and survival outcomes of primary cutaneous T-cell lymphoma among disaggregated Asian American, Native Hawaiian, and Pacific Islander populations.

Journal of the American Academy of Dermatology
2026

Histopathologic Spectrum of Primary Cutaneous T-Cell Lymphomas: Insights From a Vietnamese Case Series.

The American Journal of dermatopathology
2026

Bacterial skin colonization and systemic antibiotic treatment in patients with cutaneous T-cell lymphoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2025

Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K/AKT/mTOR Dephosphorylation.

Cancer science
2025

GATA3 as a Prognostic Marker in Early-Stage Classical Mycosis Fungoides: Association With Disease Progression and Survival Outcomes.

Cancer medicine
2025

Radiation Therapy Utilization for Primary Cutaneous T-Cell Lymphoma Is Lowest Among Patients Living in the Most Geographically Accessible Areas: An Australian Study.

International journal of radiation oncology, biology, physics
2025

Comprehensive characterization of nodal peripheral T-cell lymphoma, not otherwise specified: A report of the 2023 SH/EA4HP lymphoma workshop.

American journal of clinical pathology
2025

Care and treatment for primary cutaneous lymphoma-associated ulcers: Two case reports.

SAGE open medical case reports
2025

Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.

Immunotherapy
2025

Subcutaneous Panniculitis-Like T-Cell Lymphoma With Increased γδ T Cells: A Potential Diagnostic Pitfall.

The American Journal of dermatopathology
2025

Transient Leukemia in an Adult Dog With Cutaneous T-Cell Lymphoma.

Veterinary clinical pathology
2025

Alopecia Mimicking Lichen Planopilaris in a Patient with Mycosis Fungoides.

Skin appendage disorders
2025

Primary Cutaneous Gamma-Delta T-Cell Lymphoma Presenting With Hemophagocytic Lymphohistiocytosis in a Young Polynesian Male.

Case reports in hematology
2025

Diagnostic Challenges of Early Mycosis Fungoides in Skin of Color: A Case Report and Review.

Cureus
2025

ZNF460 enhances HADHB level by activating its transcription to promote the progression and pulmonary invasion of cutaneous T cell lymphoma.

Archives of biochemistry and biophysics
2025

Musculoskeletal Lymphoma: Imaging Features, Diagnosis, and Assessment of Treatment Response.

Radiographics : a review publication of the Radiological Society of North America, Inc
2025

Rare case of CD20-positive primary cutaneous T-cell lymphoma, NOS, with an aggressive clinical course.

Journal of clinical pathology
2025

Successfully maintained complete remission of mycosis fungoides by umbilical cord blood transplantation: a case report and literature review.

Dermatology reports
2025

Clinical Characteristics, Management and Long-Term Outcomes of 180 Patients With Early-Stage Mycosis Fungoides at a Tertiary Centre-A 34-Year Retrospective Study.

The Australasian journal of dermatology
2025

"Missed" Diagnosis of Mycosis Fungoides: A Case Report.

Clinical case reports
2024

CD4/CD8 double-negative mycosis fungoides: a review.

Dermatology reports
2025

Clinical characterization of mycosis fungoides with abnormal light reactions induced by narrow-band UVB therapy: A review of a single-center experience.

The Journal of dermatology
2024

A Rare Coexistence of Turner Syndrome and Mycosis Fungoides: A Case Report.

Journal of clinical research in pediatric endocrinology
2024

Treatment of Calcinosis in Dermatomyositis-Case Report and Review.

Journal of clinical medicine
2025

Primary cutaneous T-cell lymphoma not otherwise specified reveals a novel RAB27A variant in Griscelli syndrome type 2.

The British journal of dermatology
2024

Skin-directed radiotherapy for primary cutaneous T-cell lymphomas.

Radiation oncology journal
2024

When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses.

Dermatology reports
2024

Atypical Cutaneous Manifestation of Mycosis Fungoides: A Case Report.

Cureus
2024

Navigating Diagnostic and Therapeutic Challenges in Primary Cutaneous Gamma/Delta T-Cell Lymphoma: A Case Study of Fatal Outcomes Within Two Months.

The American Journal of dermatopathology
2024

The fifth edition of the WHO-Classification - what is new for cutaneous lymphomas?

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2024

Cutaneous Lymphoma in a Tertiary Skin Hospital and Referral Centre in Nepal.

Journal of Nepal Health Research Council
2024

Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.

Clinical and experimental medicine
2024

Primary cutaneous EBV+ extranodal NK/T-cell lymphoma of gamma/delta T-cell lineage in the posttransplantation setting.

Journal of cutaneous pathology
2024

Sézary Syndrome in West Sweden: Exploring Epidemiology, Clinical Features, and Treatment Patterns in a Registry-Based Retrospective Analysis.

Cancers
2024

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.

The Journal of dermatology
2024

Estimation of the tissue and serum levels of IL-35 in Mycosis fungoides: a case-control study.

Archives of dermatological research
2024

Null T-cell phenotype mycosis fungoides with aberrant CD20 and CD56 expression: A diagnostic dilemma.

Journal of cutaneous pathology
2024

Folliculotropic mycosis fungoides associated with follicular mucinosis: A case report and mini review.

Clinical case reports
2024

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.

Blood advances
2024

A Case Report of Mycosis Fungoides Presenting With Blister Formation.

Cureus
2024

Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2024

Pneumocystis jirovecii Pneumonia in a Patient With Localized Mycosis Fungoides Not Receiving Immunosuppressive Treatment.

Cureus
2024

Dermatology in black skin.

Anais brasileiros de dermatologia
2024

Erythrodermic mycosis fungoides: A case report.

World journal of clinical cases
2024

Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023

Cutaneous T-Cell Lymphoma (CTCL) Arising Post Kidney Transplant: A Review of Clinical Variants in the Literature.

Hematology reports
2023

A Rare and Isolated Presentation of Primary Cutaneous Anaplastic Large Cell Lymphoma on the Breast.

Cureus
2023

Updates in pathobiological aspects of anaplastic large cell lymphoma.

Frontiers in oncology
2023

Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.

Human pathology
2024

Increased risk of sepsis-caused death in Black patients with primary cutaneous T-cell lymphoma and Burkitt lymphoma: A population study of the US SEER registry.

Journal of the American Academy of Dermatology
2023

Interesting Presentation of Mycosis Fungoides in Staging on F-18 FDG PET/CT.

Nuclear medicine and molecular imaging
2023

mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy.

Cancers
2023

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.

Clinical and experimental medicine
2023

Hyperpigmented Mycosis Fungoides Masquerading as Longstanding Lichen Planus Pigmentosus: A Diagnostic Pitfall.

The American Journal of dermatopathology
2023

Is Cutaneous T-Cell Lymphoma Caused by Ultraviolet Radiation? A Comparison of UV Mutational Signatures in Malignant Melanoma and Mycosis Fungoides.

Cells
2023

Cutaneous T-cell lymphoma developing in surgical scars post cardiac surgery: A case study.

SAGE open medical case reports
2023

Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.

Healthcare (Basel, Switzerland)
2023

Concurrent Presentation of Mycosis Fungoides and Primary Cutaneous Marginal Zone LPD: Clinicopathological Study of 4 Cases and Literature Review.

The American Journal of dermatopathology
2023

Thirty Years of Experience With Ocular Adnexal T-Cell Lymphoma.

Ophthalmic plastic and reconstructive surgery
2023

Primary Cutaneous Peripheral T-Cell Lymphoma With Follicular Helper T-Cell Phenotype: Report of 2 Epstein-Barr Virus-Positive Cases.

The American Journal of dermatopathology
2022

Rapidly progressive tumor stage mycosis fungoides: A case report from Syria.

Annals of medicine and surgery (2012)
2023

Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion.

American journal of clinical dermatology
2022

Diagnostic Outcomes and Treatment Modalities in Patients with Mycosis Fungoides in West Sweden-A Retrospective Register-Based Study.

Cancers
2022

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice.

Clinical, cosmetic and investigational dermatology
2023

Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma.

Cancer medicine
2022

[New treatment concepts and combination therapies for cutaneous T-cell lymphomas].

Dermatologie (Heidelberg, Germany)
2022

Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis.

JAMA oncology
2023

Characterization of primary cutaneous T-cell lymphoma following solid organ transplantation.

International journal of dermatology
2022

New developments in skin-directed treatments of cutaneous T-cell lymphoma.

Presse medicale (Paris, France : 1983)
2022

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.

Dermatologic therapy
2022

CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study.

Disease markers
2022

A Case Report of Double Positive Peripheral T Cell Lymphoma‑ Not Otherwise Specified in A Young Pregnant Female.

Indian dermatology online journal
2021

Nivolumab in two cases of refractory mycosis fungoides erythroderma.

Central-European journal of immunology
2021

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome.

Frontiers in oncology
2022

Cutaneous T-cell lymphoma mimicking myopathy with lipoatrophy.

Neuromuscular disorders : NMD
2022

Primary cutaneous gamma/delta T-cell lymphoma in Taiwan: A series of six cases with frequent solitary presentation and relatively indolent behavior.

Journal of cutaneous pathology
2021

A Comprehensive Update of the Atypical, Rare and Mimicking Presentations of Mycosis Fungoides.

Dermatology and therapy
2021

Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.

Molecular cancer
2021

Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States Between 2013 and 2020: A Population-Based Study.

Clinical lymphoma, myeloma &amp; leukemia
2021

Evaluation of Melanocyte Loss in Mycosis Fungoides Using SOX10 Immunohistochemistry.

Dermatopathology (Basel, Switzerland)
2022

DUSP22 rearrangement in primary cutaneous T cell lymphoma with features intermediate between mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis.

Histopathology
2021

Indolent CD8+ primary cutaneous T-cell lymphoma involving the eyelid of an adolescent.

Journal of cutaneous pathology
2021

An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway.

Italian journal of dermatology and venereology
2021

Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience.

Dermatology and therapy
2021

Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.

Frontiers in immunology
2021

Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.

BMC cancer
2021

Immunophenotypic switch in cutaneous T-cell lymphoma: A series of three cases and review of the literature.

Journal of cutaneous pathology
2021

Mycosis fungoides of the vulva.

Northern clinics of Istanbul
2021

Mycosis Fungoides with Dermal Mucin Deposition: An Unusual Variant of the Most Challenging Primary Cutaneous Lymphoma.

Case reports in dermatology
2020

Prognostic factors of patients with mycosis fungoides.

Postepy dermatologii i alergologii
2020

Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides.

Acta dermato-venereologica
2020

T cell lymphoma in the setting of Sjögren's syndrome: T cells gone bad? Report of five cases from a single centre cohort.

Clinical and experimental rheumatology
2021

Comparison between the histopathological and immunophenotypical features of hypopigmented and nonhypopigmented mycosis fungoides: A retrospective study.

Journal of cutaneous pathology
2020

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP.

Diagnostics (Basel, Switzerland)
2020

Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis.

Frontiers in medicine
2020

Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.

International archives of allergy and immunology
2021

Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides?

The American Journal of dermatopathology
2020

Total skin electron beam therapy for primary cutaneous T-cell lymphomas: clinical characteristics and outcomes in a Mexican reference center.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
2020

Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.

European journal of pharmacology
2020

Mycosis Fungoides, Lymphomatoid Papulosis and Hodgkin's Lymphoma in the Same Patient: Apropos of a Possible Monoclonal Origin.

Indian journal of dermatology
2020

[LINEAR MYCOSIS FUNGOIDES IN A BLASCHKOID DISTRIBUTION].

Harefuah
2020

Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience.

Annals of diagnostic pathology
2019

High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations.

Applied immunohistochemistry &amp; molecular morphology : AIMM
2019

Two Different Extranodal Lymphomas in an HIV+ Patient: A Case Report and Review of the Literature.

Case reports in hematology
2019

Primary Cutaneous Peripheral T-Cell Lymphoma of the Hand: Case Report of a Rare Diagnosis and Review of the Literature.

Journal of hand and microsurgery
2020

T-Cell-Rich Recurrence of Primary Cutaneous Follicle Center Lymphoma After Systemic Rituximab: A Diagnostic Pitfall.

The American Journal of dermatopathology
2019

Mycosis Fungoides: A 10-year Turkish Experience.

Acta dermatovenerologica Croatica : ADC
2020

Frequent and Persistent PLCG1 Mutations in Sézary Cells Directly Enhance PLCγ1 Activity and Stimulate NFκB, AP-1, and NFAT Signaling.

The Journal of investigative dermatology
2019

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

The Lancet. Oncology
2019

Two cases of phenotypic switch of primary cutaneous T cell lymphoma after treatment with an aggressive course and review of the literature.

Virchows Archiv : an international journal of pathology
2019

Effective remission of chidamide on treatment of advanced mycosis fungoides: An unusual case report.

Dermatologic therapy
2019

Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications.

European journal of dermatology : EJD
2019

Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement.

The British journal of dermatology
2019

Sézary Syndrome, recent biomarkers and new drugs.

Chinese clinical oncology
2018

Primary cutaneous peripheral T-cell lymphoma with a late relapse solely in the ileum mimicking monomorphic epitheliotropic intestinal T-cell lymphoma.

Pathology, research and practice
2018

Sézary Syndrome Presenting With Renal Involvement.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2018

Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients.

European review for medical and pharmacological sciences
2018

Molecular pathogenesis of cutaneous lymphomas.

Experimental dermatology
2018

Total Skin Electron Beam Therapy with Rotary Dual Technique as Palliative Treatment for Mycosis Fungoides.

In vivo (Athens, Greece)
2018

Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma.

Annals of hematology
2018

Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research
2018

Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia.

Internal medicine (Tokyo, Japan)
2018

Nodal Involvement by CD30+ Cutaneous Lymphoproliferative Disorders and Its Challenging Differentiation From Classical Hodgkin Lymphoma.

Archives of pathology &amp; laboratory medicine
2017

Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute.

Anais brasileiros de dermatologia
2018

Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients.

Human pathology
2017

A rare localised nasal CD30+ primary cutaneous T-cell lymphoma following liver transplantation.

BMJ case reports
2017

Monitoring the extracorporeal photopheresis by immunophenotyping in a Sézary syndrome patient.

Porto biomedical journal
2018

Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue.

International journal of dermatology
2018

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.

Haematologica
2017

Immunohistopathological Study of c-FLIP Protein in Mycosis Fungoides.

Asian Pacific journal of cancer prevention : APJCP
2017

Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.

Future oncology (London, England)
2017

Immunohistochemistry reveals an increased proportion of MYC-positive cells in subcutaneous panniculitis-like T-cell lymphoma compared with lupus panniculitis.

Journal of cutaneous pathology
2017

[Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
2017

Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk of acute toxicities.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
2017

Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma.

Oncology research and treatment
2017

CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides.

Cancer control : journal of the Moffitt Cancer Center
2017

Management Strategies for Mycosis Fungoides in India.

Indian journal of dermatology
2017

Mycosis Fungoides: Experience in a Pediatric Hospital.

Actas dermo-sifiliograficas
2016

Primary Cutaneous T Cell Lymphoma (Gamma Delta subtype).

The Medical journal of Malaysia
2017

Clinicopathologic Variants of Mycosis Fungoides.

Actas dermo-sifiliograficas
2017

Primary Cutaneous T-cell Lymphoma with Aberrant Expression of CD20.

Acta dermato-venereologica
2016

Alemtuzumab in refractory Sézary syndrome.

Anais brasileiros de dermatologia
2016

Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.

The American Journal of dermatopathology
2016

Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature.

Medicine
2016

CD8-positive Mycosis Fungoides Masquerading as Pyoderma Gangrenosum.

Indian journal of dermatology
2016

Expression of CD31 in Mycosis Fungoides.

Anticancer research
2016

Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
2017

Expression of SOX18 in Mycosis Fungoides.

Acta dermato-venereologica
2016

How I treat mycosis fungoides and Sézary syndrome.

Blood
2017

Differential NFATc1 Expression in Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoma and Other Forms of Cutaneous T-Cell Lymphoma and Pseudolymphoma.

The American Journal of dermatopathology
2016

Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma.

The Journal of investigative dermatology
2016

Mycosis Fungoides: A Retrospective Study of 44 Swedish Cases.

Acta dermato-venereologica
2015

Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides.

Postepy dermatologii i alergologii
2016

Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.

Anticancer research
2016

Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.

Oncology and therapy
2016

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.

Haematologica
2016

Molecular genetic and cytogenetic analysis of a primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma.

International journal of hematology
2015

Therapeutic Update: Update on Cutaneous and Systemic Therapy for Primary Cutaneous T Cell Lymphoma, Mycosis Fungoides.

Journal of drugs in dermatology : JDD
2016

MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.

Oncogene
2015

Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.

International journal of radiation oncology, biology, physics
2016

Expression of CD164 on Malignant T cells in Sézary Syndrome.

Acta dermato-venereologica
2015

Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.

Anticancer research
2015

[Molecular pathogenesis of peripheral T-cell lymphoma (1): angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma].

Medecine sciences : M/S
2015

Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome.

Dermatologic clinics
2015

Folliculotropic Mycosis Fungoides as a Posttransplant Lymphoproliferative Disorder.

Pediatrics
2016

Primary cutaneous follicular helper T-cell lymphoma.

Journal of cutaneous pathology
2016

Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.

International journal of dermatology
2016

Primary Cutaneous T-cell Lymphoma With Coexpression of T-Cell Receptors αβ and γδ.

The American Journal of dermatopathology
2015

Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapy.

OncoTargets and therapy
2015

ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.

Journal of cutaneous pathology
2015

Primary Cutaneous T-cell Lymphoma With Aberrant CD-20 Expression.

Journal of drugs in dermatology : JDD
2016

HPyV6, HPyV7 and TSPyV DNA sequences detection in skin disease patients and healthy subjects.

Journal of the European Academy of Dermatology and Venereology : JEADV
2015

Pagetoid reticulosis tumor cells with double expression of TCRγδ and TCRαβ: an off-target phenomenon or genuine expression?

Journal of cutaneous pathology
2015

Altered microRNA expression in folliculotropic and transformed mycosis fungoides.

Pathology oncology research : POR
2015

'We had to change to single beds because I itch in the night': a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma.

The British journal of dermatology
2015

Recent advances in primary cutaneous T-cell lymphoma.

Current opinion in oncology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Linfoma cutâneo de células T.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Linfoma cutâneo de células T e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

Trata-se de uma categoria de neoplasia rara que compromete primariamente a pele, identificada pelo código CID-10 C84.0. Estima-se que afete entre 1 e 5 pessoas a cada 10.000 habitantes.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

5 fontes citadas no texto · 9 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. MONDO
    purl.obolibrary.org
  2. Radiotherapy dose-response of mycosis fungoides with large cell transformation.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026PMID 41271171
  3. Bacterial skin colonization and systemic antibiotic treatment in patients with cutaneous T-cell lymphoma.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026PMID 40970830
  4. GARD:6226
    GARD (NIH)
  5. Q5196687
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (2026). Linfoma cutâneo de células T. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/linfoma-cutaneo-de-celulas-t

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Linfoma cutâneo de células T

ORPHA:171901 · MONDO:0015758
Prevalência
1-5 / 10 000
CID-10
C84.0 · Micose fungóide
Ensaios
70 ativos
Medicamentos
10 registrados
Prevalência
24.0 (Europe)
MedGen
UMLS
C0079773
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Moléculas estudadas na doença
fonte: OpenTargets
Rara